A detailed history of Manufacturers Life Insurance Company, The transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 40,685 shares of RVNC stock, worth $104,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,685
Previous 42,296 3.81%
Holding current value
$104,560
Previous $108,000 3.7%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.57 - $2.57 $4,140 - $4,140
-1,611 Reduced 3.81%
40,685 $104,000
Q2 2024

Aug 14, 2024

BUY
$2.34 - $4.73 $22,466 - $45,412
9,601 Added 29.37%
42,296 $108,000
Q1 2024

May 14, 2024

SELL
$4.65 - $9.31 $34,991 - $70,057
-7,525 Reduced 18.71%
32,695 $160,000
Q4 2023

Feb 13, 2024

SELL
$5.81 - $11.2 $7,855 - $15,142
-1,352 Reduced 3.25%
40,220 $353,000
Q3 2023

Nov 15, 2023

BUY
$11.47 - $25.07 $94,742 - $207,078
8,260 Added 24.8%
41,572 $476,000
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $67,035 - $102,073
2,714 Added 8.87%
33,312 $843,000
Q1 2023

May 15, 2023

BUY
$18.36 - $35.27 $19,810 - $38,056
1,079 Added 3.53%
31,677 $1.02 Million
Q4 2022

Aug 11, 2023

BUY
$18.32 - $30.66 $57,909 - $96,916
3,161 Added 11.52%
30,598 $564,000
Q4 2022

Feb 13, 2023

BUY
$18.32 - $30.66 $57,909 - $96,916
3,161 Added 11.52%
30,598 $564,000
Q3 2022

Aug 11, 2023

SELL
$14.33 - $28.47 $7,064 - $14,035
-493 Reduced 1.77%
27,437 $740,000
Q3 2022

Nov 03, 2022

SELL
$14.33 - $28.47 $7,064 - $14,035
-493 Reduced 1.77%
27,437 $741,000
Q2 2022

Aug 11, 2023

SELL
$11.52 - $20.4 $13,052 - $23,113
-1,133 Reduced 3.9%
27,930 $385,000
Q2 2022

Aug 15, 2022

SELL
$11.52 - $20.4 $13,052 - $23,113
-1,133 Reduced 3.9%
27,930 $386,000
Q1 2022

Aug 11, 2023

SELL
$12.36 - $20.31 $32,309 - $53,090
-2,614 Reduced 8.25%
29,063 $566,000
Q1 2022

May 20, 2022

SELL
$12.36 - $20.31 $97,841 - $160,773
-7,916 Reduced 21.41%
29,063 $567,000
Q4 2021

Feb 16, 2022

BUY
$12.46 - $27.87 $6,367 - $14,241
511 Added 1.4%
36,979 $603,000
Q3 2021

Nov 12, 2021

SELL
$25.78 - $33.21 $77,520 - $99,862
-3,007 Reduced 7.62%
36,468 $1.02 Million
Q2 2021

Aug 12, 2021

BUY
$26.8 - $31.84 $98,382 - $116,884
3,671 Added 10.25%
39,475 $1.17 Million
Q1 2021

May 03, 2021

SELL
$24.03 - $29.97 $48,756 - $60,809
-2,029 Reduced 5.36%
35,804 $1 Million
Q4 2020

Feb 12, 2021

BUY
$23.41 - $28.34 $53,257 - $64,473
2,275 Added 6.4%
37,833 $1.07 Million
Q3 2020

Nov 09, 2020

BUY
$23.23 - $34.3 $43,021 - $63,523
1,852 Added 5.49%
35,558 $894,000
Q2 2020

Aug 10, 2020

BUY
$12.6 - $26.55 $32,545 - $68,578
2,583 Added 8.3%
33,706 $862,000
Q1 2020

May 15, 2020

BUY
$12.46 - $27.81 $55,608 - $124,116
4,463 Added 16.74%
31,123 $461,000
Q4 2019

Feb 14, 2020

SELL
$11.66 - $20.15 $18,481 - $31,937
-1,585 Reduced 5.61%
26,660 $433,000
Q3 2019

Nov 12, 2019

SELL
$10.22 - $14.5 $235 - $333
-23 Reduced 0.08%
28,245 $389,000
Q2 2019

Aug 14, 2019

BUY
$10.67 - $15.49 $28,712 - $41,683
2,691 Added 10.52%
28,268 $367,000
Q1 2019

May 13, 2019

BUY
$15.4 - $20.39 $75,136 - $99,482
4,879 Added 23.57%
25,577 $403,000
Q4 2018

Feb 14, 2019

SELL
$18.06 - $24.96 $26,963 - $37,265
-1,493 Reduced 6.73%
20,698 $417,000
Q3 2018

Nov 14, 2018

SELL
$23.55 - $30.1 $60,711 - $77,597
-2,578 Reduced 10.41%
22,191 $552,000
Q2 2018

Aug 14, 2018

BUY
$27.45 - $33.35 $118,666 - $144,172
4,323 Added 21.14%
24,769 $680,000
Q1 2018

May 15, 2018

BUY
$29.15 - $37.4 $66,287 - $85,047
2,274 Added 12.51%
20,446 $630,000
Q4 2017

Feb 08, 2018

BUY
$24.55 - $36.3 $5,744 - $8,494
234 Added 1.3%
18,172 $650,000
Q3 2017

Nov 14, 2017

BUY
$22.55 - $28.1 $404,501 - $504,057
17,938
17,938 $495,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.